Table 4 Performances of imaging in detecting bone metastases of prostate cancer patients with first biochemical recurrence (patient-base analysis)
Se | Sp | PPV | NPV | Accuracy | κ | |
|---|---|---|---|---|---|---|
NaF PET/CT | ||||||
On-site | 71% (5/7) | 92% (44/48) | 56% (5/9) | 96% (44/46) | 89% (49/55) | 0.96 |
Central | 86% (6/7) | 94% (45/48) | 67% (6/9) | 98% (45/46) | 93% (51/55) | |
FCH PET/CT | ||||||
On-site | 43% (3/7) | 100% (48/48) | 100% (3/3) | 92% (48/52) | 93% (51/55) | 0.86 |
Central | 57% (4/7) | 98% (47/48) | 80% (4/5) | 94% (47/50) | 93% (51/55) | |
DW-MRI | ||||||
On-site | 57% (4/7) | 83% (40/48) | 33% (4/12) | 93% (40/43) | 80% (40/55) | 0.59 |
Central | 43% (3/7) | 94% (45/48) | 60% (3/5) | 90% (45/50) | 87% (48/55) | |